Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H13N5O.ClH |
| Molecular Weight | 207.661 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC(=N)NC(=N)N1CCOCC1
InChI
InChIKey=FXYZDFSNBBOHTA-UHFFFAOYSA-N
InChI=1S/C6H13N5O.ClH/c7-5(8)10-6(9)11-1-3-12-4-2-11;/h1-4H2,(H5,7,8,9,10);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H13N5O |
| Molecular Weight | 171.2003 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Sources: https://patents.google.com/patent/GB776176A
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9868507
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.04 g/kg 1 times / day steady, Studied dose Dose: 0.04 g/kg, 1 times / day Route: steady Dose: 0.04 g/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: |
Disc. AE: Diarrhea, Itching... AEs leading to discontinuation/dose reduction: Diarrhea (2 patients) Sources: Itching (1 patient) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Itching | 1 patient Disc. AE |
0.04 g/kg 1 times / day steady, Studied dose Dose: 0.04 g/kg, 1 times / day Route: steady Dose: 0.04 g/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: |
| Diarrhea | 2 patients Disc. AE |
0.04 g/kg 1 times / day steady, Studied dose Dose: 0.04 g/kg, 1 times / day Route: steady Dose: 0.04 g/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: unknown Food Status: UNKNOWN Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] | ||||
| no [IC50 >10 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 64 | 67 |
no |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [The influense of guanidine derivatives on free radical oxidation intensity and aconitase activity at development of brain ischemia-reperfusion at rats]. | 2009-12-19 |
|
| Effect of N-[Imino(4-morpholyl)methyl]guanidine on the oxidative status in rats with toxic hepatitis. | 2009-10 |
|
| Study of molecularly imprinted solid-phase extraction of diphenylguanidine and its structural analogs. | 2009-04-20 |
|
| Trisodium bis-{1-[iminio-(morpholino)meth-yl]guanidinium} bis-[hexa-hydrogen-hexa-molybdoaluminate(III)] chloride icosa-hydrate. | 2008-07-26 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9868507
Daily dose ranges from 25 to 5600 mg.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27188236
6.3 μg/mL Moroxydine suppresses apoptosis in grass carp reovirus (GCRV)-infected Ctenopharyngodon idella kidney (CIK) cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:17:23 GMT 2025
by
admin
on
Mon Mar 31 19:17:23 GMT 2025
|
| Record UNII |
6Y9698W0XT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
63755
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
52355
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
6Y9698W0XT
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
DTXSID1045376
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
3160-91-6
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
SUB03331MIG
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
m7628
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | Merck Index | ||
|
407204
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
221-612-6
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
moroxydine hydrochloride
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
43840
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
76621
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
1291996
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | RxNorm | ||
|
47838
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY | |||
|
100000086145
Created by
admin on Mon Mar 31 19:17:23 GMT 2025 , Edited by admin on Mon Mar 31 19:17:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |